Wolfe starts J&J at Outperform, sees growth drivers as ‘best-in-class’
Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...
Hosted on MSN9h
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have lost about 6.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
FiercePharma13h
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...